Add-on Pilot Trial of Minocycline to Treat Fragile X Syndrome

Add-on Pilot Trial of Minocycline in Fragile X Syndrome

Fragile X Syndrome (FXS) is the most common known inherited form of mental impairment, developmental disability and autism. Minocycline is an antibiotic that has recently been used to treat the mouse model for Fragile X, and was found to reverse the structural abnormalities that are seen their brain cells. The purpose of this research study is to determine if minocycline is an effective treatment for patients with fragile X syndrome (FXS).

Study Overview

• Status: Completed
• Conditions: Fragile X Syndrome
• Intervention / Treatment: Drug: Minocycline

Detailed Description

Fragile X Syndrome (FXS) is the most common known inherited form of mental impairment and is also associated with a range of learning disabilities, neurological problems, such as seizures, and behavioural difficulties. For many individuals with FXS, behavioral difficulties result in severe problems within the family and community, particularly in the form of agitation, temper outbursts, hyperactivity, and aggression. These problems often require a variety of psychopharmacological and behavioural approaches. Although a variety of medications can be helpful in FXS there are no targeted interventions based on molecular abnormalities that have been studied. Defects in dendritic spine formation have been found in the brains of patients with Fragile X, suggesting these structures may represent an anatomical and physiological basis for the cognitive deficits associated with this disorder. Recent research has suggested that minocycline may have a specific benefit in the treatment of FXS. Minocycline is an antibiotic that has been found to inhibit the activity of matrix metallo-proteinase-9 (MMP-9), which is up-regulated in the hippocampus of FMR1 KO (Fragile X Mental Retardation-1 Knockout) mice and may be responsible for the immature dendritic spine profile of hippocampal neurons. Minocycline has recently been used to treat the FXS KO mouse model for Fragile X, and was found to rescue this abnormal phenotype by inducing the formation of mature dendritic spines in FMR1 KO hippocampal neurons, both in vitro and in vivo. Minocycline treated FXS KO mice also performed significantly better in the elevated maze, a cognitive performance test that measures activity and anxiety.

Exciting preclinical effects of minocycline with regard to the FXS disease model have led to this pilot proposal, which is designed to generate preliminary data that could be used to support a larger clinical trial.

The overall hypothesis is that minocycline is a specific molecular targeted treatment for FXS that will display beneficial effects on disruptive behaviour and possibly other associated features of FXS via a reduction in MMP-9 activity.

• Study Type: Interventional
• Enrollment (Actual): 20
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Canada
  • Ontario
    • Toronto, Ontario, Canada, M5S 2C2
      • Surrey Place Centre

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 11 years to 33 years (Child, Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Diagnosis of FXS by clinical evaluation and confirmed by FMR1-DNA testing with presence of full mutation or mosaicism for the full mutation. Prior DNA testing reports will be accepted, when available.
• Age between 13 to 35 years inclusive at the time of informed consent.
• Male or female
• CGI-Severity Score of 4 or greater, indicative of moderate or greater severity of behavioural problems. This is a 7-point scale of clinical global impression of severity that the clinician fills out after considering all the available information on the patient, including the parent history, the examination in clinic, reports from the school and other sources.
• Score of 9 or greater on the Aberrant Behaviour Checklist - Irritability Scale (top 50th %-tile). The ABC is a global behaviour checklist implemented for the measurement of drug and other treatment effects in mentally impaired individuals. It is made up of 5 empirically derived dimensions including irritability, lethargy/withdrawal, inappropriate speech, hyperactivity, and stereotypic behaviour based on 58 items that describe various behavioural problems.
• Availability of parent and/or caregiver for all clinic visits and assessments.
• English language fluency and reading level of 6th grade or greater in one caregiver.

Exclusion Criteria:

• Allergy to minocycline.
• Kidney disease or elevated renal function tests.
• Liver disease or elevated liver function tests.
• Participants with neutropenia, anemia, or thrombocytopenia.
• History of systemic lupus erythematosus or screening anti-nuclear antibody (ANA) titre of >1:40, as minocycline may cause a lupus-like reaction.
• Individuals who do not have a mother or caregiver who is willing to participate in the clinic visits.
• Individuals who are pregnant or at risk to become pregnant, specifically sexually active females will be excluded.
• Presence of persistent psychotic symptoms
• Subjects with symptom severity likely judged to endanger personal safety or safety of others.
• History of systemic lupus erythematosus or screening anti-nuclear antibody (ANA) titre of >1:40, as minocycline may cause a lupus-like reaction.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: minocyline 50 mg or 100 mg PO BID; open label treatment with minocycline low or high dose, 50 mg or 100 mg PO (by mouth) BID (twice a day), added to existing medication regimen for 8 weeks	Drug: Minocycline; 50-100 mg PO BID for 8 weeks with an option for a 1 year extension.; Other Names: Solodyn, Dynacin, Arestin, Minocin

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Baseline of ABC Irritability Subtest Score at 8 Weeks	The 15-item Irritability Scale includes questions about aggression, self-injury, tantrums, agitation, and unstable mood on a scale of 0 to 45 with higher scores indicating greater severity. This scale has been successfully used in previous medication studies in children with autism and in patients with FXS and in a controlled trial of ampakine CX516 in FXS. All ABC subscales showed good reliability when used by parents and caregivers of individuals with FXS to assess behavior in the CX516 study NCT00054730, and yielded intraclass correlation coefficient (ICC) values of 0.7-0.9.	Baseline and 8 weeks
ABC Irritability Subtest Score	ABC Irritability subtest score was used	8 weeks
ABC Irritability Subtest Score	ABC (Aberrant behavior checklist) Irritability subtest score was used	1 year

Secondary Outcome Measures

Outcome Measure	Time Frame
Parent Defined Target Symptoms Scale-Visual	Baseline
Clinical Global Impression Scale	Baseline
Stanford Binet 5 (SB5)	Baseline
The Peabody Picture Vocabulary Test Third Edition (PPVT-III)	Baseline
The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)	Baseline
Non-Verbal Associative Learning Task (NVALT)	Baseline
Vineland Adaptive Behaviour Scales (VABS)	Baseline
Parent Defined Target Symptoms Scale-Visual	8 weeks
Parent Defined Target Symptoms Scale-Visual	1 year
Clinical Global Impression Scale	8 weeks
Clinical Global Impression Scale	1 year
Stanford Binet 5 (SB5)	1 year
The Peabody Picture Vocabulary Test Third Edition (PPVT-III)	8 weeks
The Peabody Picture Vocabulary Test Third Edition (PPVT-III)	1 year
The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)	8 weeks
The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)	1 year
Non-Verbal Associative Learning Task (NVALT)	8 weeks
Non-Verbal Associative Learning Task (NVALT)	1 year
Vineland Adaptive Behaviour Scales (VABS)	8 weeks
Vineland Adaptive Behaviour Scales (VABS)	1 year

Collaborators and Investigators

• Sponsor: FRAXA Research Foundation
• Collaborators: Fragile X Research Foundation of Canada
• Investigators: Principal Investigator: Carlo Paribello, M.D., Fragile X Research Foundation of Canada

Publications and helpful links

General Publications

• Paribello C, Tao L, Folino A, Berry-Kravis E, Tranfaglia M, Ethell IM, Ethell DW. Open-label add-on treatment trial of minocycline in fragile X syndrome. BMC Neurol. 2010 Oct 11;10:91. doi: 10.1186/1471-2377-10-91.

Helpful Links

• The Fragile X Research Foundation of Canada is a non-profit organization which is dedicated to funding biomedical research for improved treatment and, ultimately, a cure for fragile X.
• FRAXA is a non-profit organization whose mission is to accelerate progress toward effective treatments and a cure for Fragile X, by funding the most promising research.

Study record dates

Study Major Dates

• Study Start: October 1, 2007
• Primary Completion (Actual): November 1, 2008
• Study Completion (Actual): January 1, 2009

Study Registration Dates

• First Submitted: March 9, 2009
• First Submitted That Met QC Criteria: March 9, 2009
• First Posted (Estimate): March 10, 2009

Study Record Updates

• Last Update Posted (Estimate): February 18, 2016
• Last Update Submitted That Met QC Criteria: February 16, 2016
• Last Verified: February 1, 2016

More Information

Terms related to this study

• Keywords: Clinical Drug Trial
• Additional Relevant MeSH Terms: Pathologic Processes; Nervous System Diseases; Neurologic Manifestations; Neurobehavioral Manifestations; Disease; Congenital Abnormalities; Genetic Diseases, Inborn; Genetic Diseases, X-Linked; Mental Retardation, X-Linked; Intellectual Disability; Heredodegenerative Disorders, Nervous System; Chromosome Disorders; Sex Chromosome Disorders; Syndrome; Fragile X Syndrome; Anti-Infective Agents; Anti-Bacterial Agents; Minocycline
• Other Study ID Numbers: 010308